| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.21 | 4e-06 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-06 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-06 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-06 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-05 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |